Skip to main content

Advertisement

Table 7 Comparison of various reports on the efficacy of PRRT in PGL/PCC patients

From: Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Author and year Patient number PR SD PD Death Follow-up (median, months) Median OS (months) Median PFS (months) TTP
van Essen et al. 2006 [27] 12 2 (17%) 6 (50%) 4 (33%) 2 (16%) 13 (4–30)
Forrer et al. 2008 [16] 25 2PR + 5MR (28%) 13 (52%) Mixed response 2 (8%) 6 (24%) *19 (6–50) 3 to > 42
Mean not reached
Zovato et al. 2012 [28] 4 2 (50%) 2 (50%) 0 0 *15.8 (12–25)
Pinato et al. 2016 [29] 5 1 (20%) 3 (60%) 1 (20%) 2 (40%) 13 17 (0–78) Not reached
Kong et al. 2017 [18] 20 CT scan    5 (25%) 28 Not reached 39
29% SSTR 50% 14%
47% 41% 12%
Present study 25 5 (20%) 16 (64%) 4 (16%) 7 (28%) 30 (9–60) Not reached 32 13
  1. PR partial response, SD stable disease, PD progressive disease, OS overall survival, PFS progression-free survival, TTP time to progression, MR minimal response, CT scan computed tomography scan, SSTR imaging somatostatin receptor imaging
  2. *Mean follow-up duration in months